Abstract
Dr. Saul Hertz (1905-1950) conceived and brought from bench to bedside
the medical uses of Radioiodine (RAI). Dr. Hertz established the use of
radiopharmaceuticals to diagnose and treat disease. He spontaneously posed the
question “Could iodine be made radioactive artificially?” to MIT President Karl
Compton on November 12, 1936. MGH's Dr. Hertz and his MIT collaborator, Arthur
Roberts, Ph. D., were the first and the foremost to develop the experimental data for the
medical uses of radioiodine (RAI) and apply RAI in the clinical setting. Dr. Hertz
successfully used RAI in diagnosing and treating hyperthyroidism and thyroid cancer,
believing that the targeted precision approach held the key to the larger problem of
cancer in general. RAI is the first and gold standard of targeted cancer therapies.
Hertz established the Radioactive Isotope Research Institute and The Massachusetts
Women’s Hospital’s their first Nuclear Medicine Department reported as,” Opening a
new division where radioactive isotopes will be used to study and treat disease.”
Keywords: Nuclear Medicine, Precision oncology, Radioiodine (RAI), Theranostics.
Related Books
Advances in Cancer Nanotheranostics for Experimental and Personalized Medicine
Cancer Metastasis and Cancer Stem Cell/Niche
Cancer Preventive and Therapeutic Compounds: Gift From Mother Nature
Controversies in Neuro-Oncology
Current Advances in Breast Cancer Research: A Molecular Approach
Cutting Edge Therapies for Cancer in the 21st Century
Frontiers in Cancer Immunology
Frontiers in Cancer Immunology
Frontiers in Clinical Drug Research - Anti-Cancer Agents
Frontiers in Clinical Drug Research - Anti-Cancer Agents